Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter Trop2 (Sacituzumab Biosimilar) Antikörper

Dieser Humanized Monoklonal Antikörper erkennt spezifisch Trop2 (Sacituzumab Biosimilar) in FACS und in vivo. Er zeigt eine Reaktivität gegenüber Human.
Produktnummer ABIN7795133

Kurzübersicht für Rekombinanter Trop2 (Sacituzumab Biosimilar) Antikörper (ABIN7795133)

Target

Trop2 (Sacituzumab Biosimilar)

Antikörpertyp

Recombinant Antibody

Reaktivität

Human

Wirt

  • 4
  • 1
Humanized

Klonalität

  • 4
  • 1
Monoklonal

Konjugat

  • 4
  • 1
Dieser Trop2 (Sacituzumab Biosimilar) Antikörper ist unkonjugiert

Applikation

  • 4
  • 3
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse

Research Grade
  • Expressionssystem

    Mammalian cells

    Verwendungszweck

    Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg

    Produktmerkmale

    What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.

    Aufreinigung

    Protein A or G affinity column

    Reinheit

    >95 % by reducing SDS-PAGE

    Endotoxin-Niveau

    Less than 0.5 EU/mg of protein as determined by LAL method

    Immunogen

    Human Trop-2
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Konzentration

    > 3 mg/mL

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • Target

    Trop2 (Sacituzumab Biosimilar)

    Andere Bezeichnung

    Sacituzumab Biosimilar

    Substanzklasse

    Biosimilar
Sie sind hier:
Chat with us!